DOI QR코드

DOI QR Code

이중에너지 X선 흡수법을 이용한 골밀도 측정시 99mTc-MDP 투여 전·후 측정값의 변화

Change in the Measured Value at 99mTc-MDP Administration before and after Bone Density Measurement using the Dual Energy X-ray Absorptiometry

  • Kang, Yong-Gil (Department of Nuclear Medicine, Korea University ANAM Hospital) ;
  • Won, Do-Yeon (Department of Radiological Science, Daegu health college) ;
  • Jung, Hong-Moon (Department of Radiological Science, Daegu health college)
  • 투고 : 2017.02.10
  • 심사 : 2017.02.28
  • 발행 : 2017.02.28

초록

최근 동위원소를 이용한 뼈 스캔 (Bone Scan)검사 후 골밀도 (BMD; Bone Mineral Density)검사를 당일검사로 병행한 경우 이로 인한 골밀도 측정값에 오차 발생 가능성이 제기되고 있으나 방사성의약품 표지화합물 투여 후 이중에너지 X선을 이용한 골밀도 측정값 변화에 대한 임상적 자료가 미비하여 핵의학 체내검사 후 당일 골다공증 검사의 측정값에 대한 논란의 소지가 있다. 따라서 동위원소 표지화합물인 $^{99m}Tc-MDP$가 골밀도 측정값에 영향을 미치는지 임상적 측면에서 실험하였다. 실험에 참가한 대상자의 평균 나이는 $35.17{\pm}9.45$세로 실험 대상자 17명 중 대사성 질환과 골밀도 측정에 영향을 줄 수 있는 허리뼈 압박골절 및 몸쪽 넓적다리뼈 골절이 있는 자를 제외한 12명 중 정상 골밀도 T-scores>-1.0의 환자 6명을 대상으로 $^{99m}Tc-MDP$ 투여 전 후 측정값을 분석한 결과 허리뼈에서 전 후 각각 평균 $0.975{\pm}0.084g/cm^2$, $0.966{\pm}0.078g/cm^2$으로 $0.009g/cm^2$ 증가, 우측 몸쪽 넓적다리뼈에서는 전 후 각각 평균 $0.909{\pm}0.078g/cm^2$, $0.913{\pm}0.086g/cm^2$으로 $0.004g/cm^2$ 감소, 좌측 몸쪽 넓적다리뼈에서는 각각 평균 $0.887{\pm}0.099g/cm^2$, $0.881{\pm}0.103g/cm^2$으로 $0.007g/cm^2$의 증가를 보여 몸쪽 넓적다리뼈 보다 허리뼈에서 더 큰 골밀도 변화를 보여주었다. 그러나 허리뼈와 몸쪽 넓적다리뼈 전체에서 전 후 변화 평균은 $0.0038{\pm}0.014g/cm^2$으로 골밀도 측정값에 유의한 영향이 없음을 알 수 있으며, 또한 두 실험간 전체 상관계수는 0.987으로 방사성동위원소 표지화합물인 $^{99m}Tc-MDP$ 투여가 골밀도 측정값에 영향을 주지 않았다. 따라서 140 keV의 감마선 에너지를 방출하는 테크네슘 표지화합물을 이용한 뼈 스캔검사 후 골밀도 측정값에 유의한 영향을 미치지 않음을 확인하였다. 그러나 핵의학적 체내검사와 골다공증 검사를 당일로 검사함으로 인한 환자의 피폭을 고려한다면 시간 간격을 두고 검사를 시행하는 것이 좋을 것으로 사료된다.

Measurement of bone marrow measurements may occur if bone marrow examination performed with bone marrow examination (bone marrow examination) and bone density (bone scan) are performed together recently. Thus, it was examined in clinical aspects that $^{99m}Tc-MDP$ compounds were affected by bone mineral density measurements. The average age of the participants in the experiment was $35.17{\pm}9.45$ and the patient fractures of the lumbar vertebrae that could affect the metabolic disease and bone density measurements affecting the metabolic disease of the 17 subjects. 6 patients with normal bone mineral density T-scores>-1.0 in 12 patients were analyzed before and after the administration of $^{99m}Tc-MDP$. In the lumbar spine, the average of $0.975{\pm}0.084g/cm^2$ and $0.966{\pm}0.078g/cm^2$ were increased by $0.009g/cm^2$. respectively In the right proximal femur, mean values were $0.909{\pm}0.078g/cm^2$ and $0.913{\pm}0.086g/cm^2$. In the right proximal thigh, mean values were $0.909{\pm}0.078g/cm^2$ and $0.913{\pm}0.08 g/cm^2$, respectively, which decreased by $0.004g/cm^2$. In the left side proximal femur, mean $0.887{\pm}0.099g/cm^2$ and $0.881{\pm}0.103g/cm^2$, respectively, increased by $0.007g/cm^2$. Therefore, the BMD changes in the lumbar region were larger than that in the proximal thigh. In addition, $^{99m}Tc-MDP$ did not affect the BMD. And a bone scan test using a technetium-labeled compound emitting a gamma-ray energy of 140 keV did not significantly affect bone density measurements. However, if the nuclear medical examination and the osteoporosis test are to be performed together, the examination should be carried out at intervals considering the exposures of the patient.

키워드

참고문헌

  1. J. A. Kanis, "Osteoporosis and osteopenia," Journal of Bone and Mineral Research, Vol. 5, pp. 209-211, 1990. https://doi.org/10.1002/jbmr.5650050302
  2. J. A. Kanis, L. J. Melton, C. Christiansen, C. C. Johnston and N. Khaltaev, "The diagnosis of osteoporosis" Journal of Bone and Mineral Research, Vol. 9, No. 8, pp. 1137-1141, 1994. https://doi.org/10.1002/jbmr.5650090802
  3. J, W Cobum, D. L. Hartenbower, S. G. Massry, "Intestinal absorption of calcium and the effect of renal insufficiency," Kidney International, Vol. 4, No. 2, pp. 96-104, 1973. https://doi.org/10.1038/ki.1973.88
  4. K. A. Hruska, R. Kopelman, W. E. Rutherford, S. Klahr, E. Slatopolsky, A. Greenwalt, T. Bascom, J. Markham, "Metabolism of immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronicrenal disease," Journal of Clinical Investigation, Vol. 56, No. 1, pp. 39-48, 1975. https://doi.org/10.1172/JCI108077
  5. F. Llach, S. G. Massry, F. R. Singer, K. Kurokawa, J. H. Kaye, J. W. Coburn, "Skeletal resistance to endogenous parathyroid hormene in patients with early renal failure," Journal of Clinical Endocrinology and Metabolism, Vol. 41, No. 2, pp. 339-345, 1975. https://doi.org/10.1210/jcem-41-2-339
  6. P. Sambrook, C. Cooper, "Osteoporosis," The Lancet Seminars, Vol. 367, No. 9527, pp. 2010-2018, 2006. https://doi.org/10.1016/S0140-6736(06)68891-0
  7. R. D. Wasnich, P. D. Ross, L. K. Heilbrun, J. M.. Vogel, "Prediction of postmenopausal fracture risk with use of bone mineral measurements," American Journal of Obstetrics and Gynecology, Vol. 153, No. 7, pp. 745-751, 1985. https://doi.org/10.1016/0002-9378(85)90338-2
  8. S. L Hui, C. W Slemenda, C. C Johnston, "Age and bone mass as predictors of fracture in a prospective study," Journal of Clinical Investigation, Vol. 81, No. 6, pp. 1804-1809, 1988. https://doi.org/10.1172/JCI113523
  9. C. L. Benhamou, "Effects of osteoporosis medications on bone quality," Joint Bone Spine, Vol. 74, No. 1, pp. 39-47, 2007. https://doi.org/10.1016/j.jbspin.2006.06.004
  10. V. Ravenda, R. Mertens, V. Fabri, J. Vanoverloop, F. Sumkay, C. Vannecke, A. Deswaef, G. A. Verpooten, J. Y. Reginster, "Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women," Osteoporosis International, Vol. 19, No. 6, pp. 811-818, 2007. https://doi.org/10.1007/s00198-007-0506-x
  11. C. L. Gamble, "Osteoporosis: Making the diagnosis in patients at risk for fracture," Geriatrics, Vol. 50, No, 7, pp. 24-33, 1995.
  12. B. L. Riggs, L. J. Melton, Osteoporosis, 2nd ed., Philadelphia Lippincott-Raven Co., pp. 2778-283, 1995.
  13. A. J. Yates, P. D. Ross, E. Lydick, R. S. Epstein, "Radiographic absorptiometry in the diagnosis of osteoporosis," American Journal of Medicine, Vol. 98, No. 2A, pp. 41S-47S, 1995. https://doi.org/10.1016/S0002-9343(05)80045-2
  14. K. W. Lee, J. H. Kim, P. J. Whang, M. H. Shong, Y. K. Kim, H. K. Ro et. al, "Serum iPTH Level and Bone Mineral Density in Patients with Non-Insulin Dependent Diabetic End Stage Renal Disease (ESRD) at the Beginning of Renal Replacement Therapy," Chungnam Medical Journal, Vol. 26, No. 1, 1999.